
Please try another search
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Name | Age | Since | Title |
---|---|---|---|
Karen Linehan | 66 | 2022 | Independent Director |
Pier Vincenzo Piazza | 64 | 2017 | CEO & Director |
Francois Thomas | 68 | 2022 | Observer |
Irina Staatz-Granzer | 65 | 2022 | Independent Director |
Anders Gersel Pedersen | 74 | 2020 | Independent Chairman of the Board |
Robert C. Malenka | - | - | Chairman of the Scientific Advisory Board |
Daniele Piomelli | - | - | Member of Scientific Advisory Board |
Markus Heilig | - | - | Member of Scientific Advisory Board |
Brahim Guetarni | 54 | 2021 | Director |
Keith Humphreys | - | - | Member of Scientific Advisory Board |
Karina Hansen | 52 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review